{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:50:57Z","timestamp":1788879057610,"version":"build-2803163510"},"reference-count":39,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:p>BACKGROUND: The biological roles of immune-related genes (IRGs) in bladder cancer (BC) need to be further elucidated. OBJECTIVE: To elucidate the predictive value of IRGs for prognosis and immune escape in BC. METHODS: We comprehensively analyzed the transcriptomic and clinical information of 430 cases, including 19 normal and 411 BC patients from the TCGA database, and verified 165 BC cases in the GSE13507 dataset. The risk model was constructed based on IRGs by applying LASSO Cox regression and exploring the relationship between the risk score and prognosis, gene mutations, and immune escape in BC patients. RESULTS: We identified 4 survival-related genes (PSMC1, RAC3, ROBO2 and ITGB3) among 6,196 IRGs in both the TCGA and GES13507 datasets,, which were used to establish a gene risk model by applying LASSO Cox regression. The results showed that the high-risk (HR) group was closely associated with poor survival or advanced pathological stage of BC. Furthermore, the risk score was found to be an independent risk factor for prognosis of BC patients. In addition, high-risk individuals showed a greater prevalence of TP53 mutations lower CD8+ T-cell and NK cell infiltration, higher Treg cell infiltration, higher expression of PD-L1, and higher immune exclusion scores than those in the low-risk (LR) group. Finally, the experimental verification shows that the model construction gene, especially PMSC1, plays an important role in the growth and metastasis of bladder cancer. CONCLUSIONS: These evidences revealed the vital role of IRGs in predicting prognosis, TP53 mutation and immune escape in BC patients.<\/jats:p>","DOI":"10.3233\/cbm-230190","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T07:10:36Z","timestamp":1701846636000},"page":"567-581","source":"Crossref","is-referenced-by-count":3,"title":["A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer"],"prefix":"10.1177","volume":"38","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Song","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Qi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-She","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Kun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Chen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-230190_ref1","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/CBM-230190_ref2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.3233\/CBM-230190_ref3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-230190_ref4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.3233\/CBM-230190_ref5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.3233\/CBM-230190_ref6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00262-021-03098-w","article-title":"Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer","volume":"71","author":"Sun","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.3233\/CBM-230190_ref7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"10.3233\/CBM-230190_ref8","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2021.23"},{"key":"10.3233\/CBM-230190_ref9","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ucl.2020.10.005","article-title":"The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer","volume":"47","author":"Nair","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.3233\/CBM-230190_ref10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.3233\/CBM-230190_ref11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.3233\/CBM-230190_ref12","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J Urol"},{"key":"10.3233\/CBM-230190_ref13","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.3233\/CBM-230190_ref14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.21037\/tau-20-1436","article-title":"Narrative review: update on immunotherapy and pathological features in patients with bladder cancer","volume":"10","author":"Aurilio","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.3233\/CBM-230190_ref15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-018-0693-y","article-title":"Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma","volume":"20","author":"Koshkin","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.3233\/CBM-230190_ref16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-017-0748-7","article-title":"Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives","volume":"77","author":"Farina","year":"2017","journal-title":"Drugs"},{"key":"10.3233\/CBM-230190_ref17","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.3390\/ijms22062818","article-title":"Cell Therapies in Bladder Cancer Management","volume":"22","author":"Morales","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.3233\/CBM-230190_ref18","doi-asserted-by":"publisher","first-page":"915171","DOI":"10.3389\/fonc.2022.915171","article-title":"CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.3233\/CBM-230190_ref19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fgene.2020.00607","article-title":"Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer","volume":"11","author":"Chen","year":"2020","journal-title":"Front Genet"},{"key":"10.3233\/CBM-230190_ref20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12885-023-11209-2","article-title":"TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle","volume":"23","author":"Jiang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-230190_ref21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-230190_ref22","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.18632\/aging.203345","article-title":"Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer","volume":"13","author":"Kao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.3233\/CBM-230190_ref23","doi-asserted-by":"publisher","first-page":"e34414","DOI":"10.1371\/journal.pone.0034414","article-title":"Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening","volume":"7","author":"Dahlman","year":"2012","journal-title":"PLoS One"},{"key":"10.3233\/CBM-230190_ref24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s11033-014-3110-0","article-title":"MiR-320a down-regulation mediates bladder carcinoma invasion by targeting ITGB3","volume":"41","author":"Shang","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.3233\/CBM-230190_ref25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12253-013-9722-1","article-title":"Down-regulation of ROBO2 expression in prostate cancers","volume":"20","author":"Choi","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.3233\/CBM-230190_ref26","doi-asserted-by":"publisher","first-page":"e141083","DOI":"10.1172\/JCI141083","article-title":"SLIT2\/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia","volume":"131","author":"Geraldo","year":"2021","journal-title":"J Clin Invest"},{"key":"10.3233\/CBM-230190_ref27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fmolb.2020.00218","article-title":"RAC3 Promotes Proliferation, Migration and Invasion via PYCR1\/JAK\/STAT Signaling in Bladder Cancer","volume":"7","author":"Cheng","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.3233\/CBM-230190_ref28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular Subtypes of Bladder Cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.3233\/CBM-230190_ref29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.3233\/CBM-230190_ref30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"10.3233\/CBM-230190_ref31","doi-asserted-by":"publisher","first-page":"1492\u20131502","DOI":"10.1101\/gad.282145.116","article-title":"RB1: a prototype tumor suppressor and an enigma","volume":"30","author":"Dyson","year":"2016","journal-title":"Genes Dev"},{"key":"10.3233\/CBM-230190_ref32","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 Loss in Cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.3233\/CBM-230190_ref33","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.neo.2022.100814","article-title":"Therapeutic significance of ARID1A mutation in bladder cancer","volume":"31","author":"Conde","year":"2022","journal-title":"Neoplasia"},{"key":"10.3233\/CBM-230190_ref34","doi-asserted-by":"publisher","first-page":"e155899","DOI":"10.1172\/jci.insight.155899","article-title":"ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors","volume":"7","author":"Rehman","year":"2022","journal-title":"JCI Insight"},{"key":"10.3233\/CBM-230190_ref35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.3233\/CBM-230190_ref36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.3233\/CBM-230190_ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0191-1"},{"key":"10.3233\/CBM-230190_ref38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.3233\/CBM-230190_ref39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.03.049","article-title":"and European Association of Urology\u2013Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU), First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis","volume":"151","author":"Mori","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-230190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:10:31Z","timestamp":1777385431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/CBM-230190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":39,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/cbm-230190","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}